Citations

Clear

3042 citation(s) found for "Kumar, S".

Anti‐γ‐aminobutyric acid B receptor autoimmune encephalitis: Clinical presentation and diagnostic insights
Paramasivan, Naveen Kumar , McCombe, Jennifer A. , Fryer, James P., Datta, Abhigyan , Upadhyay, Nihar, Britton, Jeffrey W. , McKeon, Andrew , Mills, John R. , Ζεκερίδου, Αναστασία , Dubey, Divyanshu , Paramasivan, Naveen K , Stabile, Andrea , Datta, Abhigyan , Rezk, Mohamed , Britton, Jeffrey W , Flanagan, E P , McKeon, Andrew , Mills, J R , Pittock, S J , Zekeridou, Anastasia , Dubey, Divyanshu , Rezk, Mohamed, Upadhyay, Nihar, Flanagan, Eoin P. , Pittock, Sean J.

Mayo Clinic

Epilepsia | September 30, 2025 | Volume: 67 | Issue: 1 | Pages: 187-198

10.1111/epi.18654 | PMID 41026401 Get It

Abstract Objectives γ‐Aminobutyric acid B receptor (GABA B R)‐IgG (immunoglobulin G) is an intermediate‐risk paraneoplastic autoantibody often associated with seizures. We aimed to assess the clinical and oncological features of GABA B R‐IgG autoimmune encephalitis (AE) and evaluate the performance of antibody testing. Methods Patients testing positive for GABA B R‐IgG in serum/cerebrospinal fluid (CSF) at Mayo Clinic Neuroimmunology Laboratory were identified. Archived sera were retested by cell‐based assay (CBA) at 1:100 and 1:200 dilutions. A live‐cell flow cytometry–based assay (LCFBA) was developed and validated using archived sera and CSF. True positivity included patients with classic presentations of GABA B R‐IgG AE or oncological explanations for antibody presence. Results Eighty‐six patients (median age 63 years; 43 female) presented with classic presentations of GABA B R‐IgG AE: encephalopathy with prominent seizures ( n = 55), status epilepticus ( n = 23), and rapidly progressive dementia ( n = 8). In addition, 44 patients (33%) had a false‐positive result for GABA B R‐IgG characterized by non‐specific symptoms/alternate diagnoses. Malignancy was identified in 78% of true‐positive patients, predominantly small cell lung carcinoma (SCLC). Testing serum at 1:100 dilution on CBA and using tissue immunofluorescence assay (IFA) in serum and CSF improved the identification of true‐positive patients ( p < 0.001). CBA at 1:100 dilution performed better than conventional CBA (at 1:10 dilution, p < 0.001) and tissue IFA ( p = 0.031). An in‐house LCFBA showed 100% sensitivity and specificity in CSF, performing similarly to conventional CBA ( p = 0.125) in CSF, but better than tissue IFA ( p = 0.031). Furthermore, serum LCFBA performed better than conventional CBA ( p = 0.022) and tissue IFA ( p = 0.006). LCFBA had the highest diagnostic accuracy and was closely followed by CBA at 1:100 dilution. Significance GABA B R‐IgG AE often presents as encephalopathy with seizures or status epilepticus in the context of an underlying SCLC. Multimodal evaluation using tissue IFA and fixed CBA at higher dilutions improves detection of true cases. LCFBA performs very well as a diagnostic test with very high sensitivity and specificity.
Weight Loss Effect of Lisdexamfetamine in Children with Severe Obesity: A Case Series
Hassan, Doha , Pittock, Siobhán T. , Kumar, Seema, Pittock, Siobhan , Salama, Mostafa

Mayo Clinic

Childhood Obesity | September 30, 2025 | Volume: 21 | Issue: 8 | Pages: 641-647

10.1177/21532176251385703 | PMID 41022566 Get It

Background: Pharmacological options for severe obesity in early childhood are limited. While lisdexamfetamine is approved for attention-deficit/hyperactivity disorder (ADHD) and binge eating disorder, its role in managing obesity in children without these conditions has not been well studied. This case series assessed the effect of lisdexamfetamine on weight in young children with severe obesity but without ADHD or binge eating disorder. Methods: We conducted a retrospective chart review of six children with severe obesity treated with lisdexamfetamine for weight management. Demographic, anthropometric, and metabolic data were collected. One patient had Prader–Willi syndrome (PWS); the others had no known syndromic obesity. Results: Median age at treatment initiation was 6.5 years (range: 4.5–14), with equal male and female distribution. Median treatment duration was 12 months (range: 12–24), and mean maximum tolerated lisdexamfetamine dose was 35 mg (range: 10–60). In patients without syndromic obesity (n = 5) including one child with hypothalamic obesity, lisdexamfetamine significantly reduced body mass index (BMI) percent of the 95th percentile at 12 months (median change –24%, range: −18 to −28, p = 0.031), equating to a 13.8% reduction in BMI. Height percentile remained unchanged ( p = 0.59). The patient with PWS did not achieve lasting weight loss. Three children reported decreased appetite. Conclusions: Lisdexamfetamine was associated with weight loss in young children with severe obesity without genetic syndromes. Further studies are warranted to assess the long-term efficacy and safety of lisdexamfetamine in the management of pediatric obesity.
A Bibliometric Review of Capsular Contracture in Breast Implant: Global Trends and Research Hotspots
Kumar, Nishant , Ravi, Vasupriya , Gates-Tanzer, Lauren, Coppa, Michaelangelo, Martinez‐Jorge, Jorys, Paget, James T, Vijayasekaran, Aparna , Coppa, Michaelangelo, Paget, James

Mayo Clinic

Plastic Surgery | September 29, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/22925503251379894 | PMID 41036451 Get It

Introduction: Capsular contracture (CC) is the most common complication following breast augmentation and reconstruction. Although numerous risk factors and preventive strategies have been proposed, the etiology remains poorly understood. This study employs bibliometric analysis to evaluate global research trends, collaboration networks, and emerging hotspots in CC research. Methods: We queried the Web of Science Core Collection using keywords related to breast implants and CC, including publications through December 31, 2024. Data including publication year, author, institution, citations(C), and keywords were analyzed using VOSviewer , Microsoft Excel , and Scimago Graphica to visualize trends, collaboration networks, and research foci. Results: A total of 2065 publications(P) were included. The United States led in both total publication output and citation count (P = 800, C = 27 984), with Harvard (P = 48, C = 1688) and Georgetown Universities (P = 45, C = 2750) being key contributors. Emerging contributions from Asian institutions were noted, though citation impact remained lower. Plastic and Reconstructive Surgery was the most prolific and cited journal (P = 473, C = 23 113). Recent research hotspots identified through keyword analysis include Biofilm , Acellular Dermal Matrix (ADM) , Implant placement , contamination , and inflammation . Most top-cited studies were of Level IV or V evidence. Conclusion: Research on CC is increasing, with a shift toward exploring biological mechanisms like biofilm formation and preventative measures such as ADM and implant positioning. Despite growing international interest, most evidence remains low quality. Future work should prioritize clinical studies that generate higher level of evidence and foster broader global collaboration to improve patient outcomes and refine surgical practices.
Short-course versus long-course antibiotic treatment for ventilator-associated pneumonia: A systematic review and meta-analysis of randomized controlled trials
Fite, Amsalu, Farooqi, Mashood , Antil, Priya, Tammineedi, Sai Niharika , Gami, NK, Komminni, Praveen Kumar , Taqi, Batoul Ali, Shaikh, Samreen Rizwan Ahmed, Sahra, Syeda , Torres, Antoni, Kakish, Diala Ra’Ed Kamal , Ahmed, Muhammad Saad , Gami, Nihar Yogesh, Cheema, Huzaifa Ahmad , Singh, Harpreet , Ahmad, Sharjeel , Ahmad, Faran , Torres, Antoní

Mayo Clinic

Canadian Journal of Respiratory, Critical Care, and Sleep Medicine | September 25, 2025 | Volume: 9 | Issue: 5 | Pages: 247-254

10.1080/24745332.2025.2552193 Get It

Hospital and Temporal Variations in Limitations of Care Among Hospitalized Patients with COVID-19: A VIRUS Registry Retrospective Cohort Study
Mesfin, Nathan , Jain, Nitesh , Mushtaq, Hisham, Jama, Abbas B, Attallah, Noura , Hassan, Esraa, Ingraham, Nicholas E. , Garces, Juan Pablo Domecq , Armaignac, Donna Lee , Perkins, Nicholas , Belden, Katherine , Kumar, Vishakha K. , Boman, Karen , Sanghavi, Devang , Bansal, Vikas , Cartin‐Ceba, Rodrigo , Nou, Abigail La, Dudley, R. Adams , Khan, Syed Anjum , Group, on behalf of the Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): Covid-19 Registry Investigator, Koritala, Thoyaja , Sanghavi, Devang K., Khedr, Anwar , Langworthy, Benjamin , Bansal, Vikas, Kashyap, Rahul, Walkey, Allan J. , Group, on behalf of the Society of Critical Care Medicine Discovery Viral Infection and Respiratory Illness Universal Study (VIRUS): Covid-19 Registry Investigator

Mayo Clinic

Palliative Medicine Reports | September 25, 2025 | Volume: 6 | Issue: 1 | Pages: No page available

10.1177/26892820251380523 | PMID 41142473 Get It

Introduction: Life-support limits (i.e., code status), the first step in the continuum of palliation and end-of-life (EoL) care, stem from decisions made by patients and their providers to align care near the EoL with patients’ wishes. The pandemic created health care strain that may have influenced life-support limitation practices among patients with serious COVID-19. In this study, we examine variations in life-support limitations (do-not-resuscitate, DNR; do-not-intubate, DNI) depending on the hospital and period of hospitalization. Methods: We included all adults admitted to a hospital in the United States with COVID-19 from January 2020 to December 2021 using the VIRUS registry. Our outcome was any life-support limitation on admission (DNR, DNI, or both) using regression modeling. Main exposures were hospital and period of hospitalization (early vs. late pandemic). Covariates included age, sex, race/ethnicity, comorbidities, and hospitalization diagnoses. Results: There were 42,383 patients from 75 hospitals in the US. The median age was 63 (interquartile range: 50–75), 46.5% were female, and 37.5% were non-Hispanic White. The life-support limitation rate was 7.9%, and the palliative care consultation rate was 2.3%. The odds of life-support limitation were 1.86 (95% CI: 1.6–2.1) depending on the hospital, but the period of hospitalization was not associated with odds of life-support limitation. Older age was associated with the greatest increased odds (4.1 per standard deviation ∼ 17.9 years, 95% CI: 3.9–4.4), followed by comorbidities including paralysis (2.4, 95% CI: 1.8–3.0) and dementia (2.3, 95% CI: 2.0–2.6). Conclusions: After adjusting for patient-level factors, we report significant inter-hospital but no temporal variation in life-support limitation upon admission with COVID-19. Future studies should investigate specific practices that led to health care resilience to temporal practice variations in life-support limitation during the pandemic.
Appropriate Selection or Poor Triaging: Assessment of Patient Profiles Presenting to a Neuromodulation for Pain Program at a Tertiary Academic Center
Gunasekaran, Prabu, Darville, Rasheeda, Alomari, Abeer , Alvares, Danielle, Bains, Victoria, Robertson, Emma , Kumar, Pranab, Baig, Ehtesham, D’Souza, Ryan S. , D'Souza, Ryan S , Gunasekaran, Prabu, Robertson, Emma, Kumar, Pranab, Hoydonckx, Yasmine , Bhatia, Anuj

Mayo Clinic

A&A Practice | September 23, 2025 | Volume: 19 | Issue: 9 | Pages: e02053

10.1213/xaa.0000000000002053 | PMID 40985557 Get It

Spinal cord stimulation (SCS) is effective for some pain syndromes, but inappropriate referrals can frustrate patients and misuse resources. This retrospective study reviewed 370 patients referred to a Neuromodulation for Pain Program (NPP) from July 2022 to June 2024. Of these, 241 were deemed appropriate for SCS. The SCS-appropriate group had higher pain intensity, more neuropathic pain, and lower opioid use. Inappropriate referrals were often from family physicians. Key factors associated with inappropriateness included low pain intensity, lack of neuropathic features, and high opioid use. Enhancing referral quality through targeted education may improve care and system efficiency.
Sex differences in chemotherapy completion, toxicities, and survival in colon cancer: an analysis of 2201 patients from CALGB/SWOG 80702 (Alliance)
Cheng, En , Shi, Qian , Shields, Anthony F. , Xue, Xiaonan , Rohan, Thomas E. , Kuang, Chaoyuan , Shergill, Ardaman , Ma, Chao , Couture, Felix, Kuebler, J. Philip , Kumar, Pankaj , Krishnamurthi, Smitha , Ng, Kimmie , Meyerhardt, Jeffrey A. , Krishnamurthi, Smitha , Ng, Kimmie , O'Reilly, Eileen M , Brown, Justin C , Meyerhardt, Jeffrey A , Shi, Qian , Couture, Felix, Kumar, Pankaj , Tan, Benjamin, O’Reilly, Eileen M. , Brown, Justin C. , Cheng, En

Mayo Clinic

JNCI: Journal of the National Cancer Institute | September 20, 2025 | Volume: 117 | Issue: 12 | Pages: 2643-2652

10.1093/jnci/djaf281 | PMID 40996326 Get It

Abstract Background Completing adjuvant chemotherapy and reducing toxicities are critical for maximizing survival after a colon cancer diagnosis. Sex, as a biological variable, may affect colon cancer chemotherapy completion, toxicities, and survival differently. Methods From a National Cancer Institute–sponsored trial conducted among patients with stage III colon cancer (Cancer and Leukemia Group B (Alliance)/Southwest Oncology Group 80702), we included 2201 patients receiving the standard adjuvant chemotherapy regimen of fluorouracil, leucovorin, and oxaliplatin. We calculated relative dose intensity to indicate chemotherapy completion and considered reduced relative dose intensity (values &lt;85%) as a clinically significant deviation from standard fluorouracil, leucovorin, and oxaliplatin. Using National Cancer Institute’s Common Terminology Criteria for Adverse Events, we defined severe adverse events (grade ≥3) as the occurrence of any following event, including neutrophil count decrease, nausea, platelet count decrease, hypertension, peripheral neuropathy, diarrhea, fatigue, gastritis, creatinine level increase, gastric ulcer, myocardial ischemia, and cerebral ischemia. The primary survival outcome was disease-free survival (time from enrollment to colon cancer recurrence or death from any cause), and secondary survival outcomes were recurrence-free and overall survival. Results Compared with men, women were at statistically significantly higher risks of experiencing reduced relative dose intensity (adjusted odds ratio = 1.59, 95% CI = 1.29 to 1.96; P &lt; .001) and severe advance events (adjusted odds ratio = 1.72, 95% CI = 1.41 to 2.11; P &lt; .001). Yet, women had statistically significantly better disease-free survival (adjusted hazard ratio = 0.72, 95% CI = 0.59 to 0.87; P &lt; .001) as well as better recurrence-free and overall survival. Conclusions Our findings suggested that women with colon cancer are more likely to have worse chemotherapy completion rates and more severe adverse events, but they have better survival. Sex as a biological variable warrants further consideration in chemotherapy administration and survivorship management after colon cancer diagnosis.
Evolving clinical burden of inflammatory bowel disease in the United Arab Emirates: a two-decade analysis of diagnoses and disease severity
Ahmed, Hosameldin Abdelrahman, Alzaabi, Mohamed Nasir, Swaid, Thaer Khaleel, Khan, Shaima , Ali, Ameirah Badr Abdullah Al, Tenaiji, Khalifa Al, Alahmad, Maryam A, Omar, Nadeen Mamon, Ahmed, Enas Fouad, Hosani, Ibrahim Al, Ahmed, Ishtiaq, Kumar, Kishore Kumar Chitra, Bukasa, Laurette L, Jess, Tine, Marzooqi, Saeed H Al, Malik, Talha A, Quraishi, Mohammed Nabil , Jess, Tine , Jess, T , Ahmed, Hosameldin Abdelrahman, Alzaabi, Mohamed Nasir, Swaid, Thaer Khaleel, Khan, Shaima Wasim , Ali, Ameirah Badr Abdullah Al, Tenaiji, Khalifa Al, Alahmad, Maryam A, Omar, Nadeen Mamon, Ahmed, Enas Fouad, Hosani, Ibrahim Al, Ahmed, Ishtiaq, Kumar, Kishore Kumar Chitra, Bukasa, Laurette L, Marzooqi, Saeed H Al, Malik, Talha A, Quraishi, Mohammed Nabil

Mayo Clinic

Frontline Gastroenterology | September 16, 2025 | Volume: 17 | Issue: 4 | Pages: 312-321

10.1136/flgastro-2025-103345 Get It

Objective Inflammatory bowel disease (IBD) is increasingly recognised in the Middle East, but limited regional data hinder a clear understanding of its burden. We aimed to examine trends in IBD diagnoses, disease phenotypes and predictors of poor outcomes at a major tertiary referral centre in the United Arab Emirates (UAE). Methods In this retrospective observational study, we evaluated diagnostic trends in a cohort of 600 Arab patients between 2002 and June 2025 and analysed detailed phenotypes in a subcohort of 414 patients diagnosed since 2012. Results We observed a nearly 13-fold increase in new IBD diagnoses among Arab patients at our centre between 2002 and 2024. This cohort (median age at diagnosis 25 years; 65% Crohn’s disease (CD; n=269), 35% ulcerative colitis (UC; n=145)) demonstrated a sharper rise in CD compared with UC, with CD being diagnosed at a significantly younger age (median 25 years vs 30 years, p=0.001). A substantial proportion of patients with CD presented with complicated disease defined as stricturing (B2; 22%, n=59), penetrating (B3; 17%, n=46) and perianal (34%, n=92) disease. Ileocolonic (L3) disease was a significant predictor for presenting with a complicated phenotype (OR 3.89). Penetrating (OR 13.9), stricturing (OR 3.38) and perianal (OR 2.22) disease were significant predictors for requiring surgery. 84% of patients with CD and 62% of patients with UC were exposed to advanced therapy. A diagnosis of CD and younger age at diagnosis were associated with a higher likelihood of needing advanced therapy. Conclusions This study provides the most comprehensive data set on IBD diagnoses and phenotypes in the UAE to date, highlighting a pronounced rise in IBD overall and of aggressive disease presentations in CD in particular.
Stereotactic Radiosurgery Versus Observation in Small- and Medium-Sized Vestibular Schwannoma Patients With Normal Hearing: A Retrospective International Multicenter Study
Hajikarimloo, Bardia , Ishaque, Mariam , Samanci, Yavuz, Pelcher, Isabelle , Begley, Sabrina , Goenka, Anuj , Schulder, Michael , Tourigny, Jean-Nicolas, Hamel, Andréanne, Briggs, Robert G. , Yu, Cheng , Zada, Gabriel , Giannotta, Steven L. , Palque, Sarai, Kumar, Narendra , Rogowski, Brandon, Shepard, Matthew J., Vasconcellos, Fernando De Nigris , Bernstein, Kenneth , Sheehan, Jason P. , Johnson, Bryan A, Sheehan, Jason , Bin-Alamer, Othman , Tos, Salem M , Mantziaris, Georgios , Abou‐Al‐Shaar, Hussam , Peker, Selçuk , Samancı, Yavuz , Mathieu, David , Speckter, Herwin , Tripathi, Manjul , Kumar, Saurabh , Kaur, Rupinder , Johnson, Bryan A., Trifiletti, Daniel M. , Warnick, Ronald E. , Mashiach, Elad , Schnurman, Zane , Alzate, Juan Diego , Kondziolka, Douglas

Mayo Clinic

Neurosurgery | September 16, 2025 | Volume: 98 | Issue: 4 | Pages: 887-894

10.1227/neu.0000000000003734 | PMID 40956102 Get It

BACKGROUND AND OBJECTIVES: The therapeutic approach for small- and medium-sized vestibular schwannoma (VS) with normal hearing function remains controversial, with limited comparative data regarding hearing outcomes after stereotactic radiosurgery (SRS) or observation (OBS). We evaluated the serviceable hearing preservation, loss of American Academy of Otolaryngology-Head and Neck Surgery class A hearing, and tumor control (TC) across individuals with Koos grade I and II VSs and normal hearing at presentation who underwent SRS or OBS. METHODS: In this multicenter international study, we retrospectively analyzed the hearing, radiological, and neurological outcomes of patients who underwent SRS (SRS group) or OBS (OBS group). The cohorts were matched using propensity scores based on age, sex, tumor volume, pure-tone average, and speech discrimination score at a 1:1 ratio without replacement. RESULTS: After matching, each group comprised 57 patients. The median follow-up was 49 and 37 months for the SRS and the OBS groups, respectively ( P = .3). The 5- and 9-year serviceable hearing preservation rates in the SRS group were 76.2% and 42.4% vs 56.1% and 16.8% in the OBS group ( P = .17). Class A preservation occurred in 57.9% (33/57) of the SRS and 52.6% (30/57) of the OBS cohorts ( P = .70). Regarding the TC rates, SRS was associated with significantly higher TC rates ( P < .0001). CONCLUSION: We found that SRS is significantly superior regarding TC and provided noninferior hearing outcomes compared with OBS in VS patients with American Academy of Otolaryngology-Head and Neck Surgery class A hearing at presentation. Therefore, we suggest performing SRS in individuals with VS and normal hearing function.
Two-channel sodium-ion conducting polymer electrolytes based on perfluorinated linear hetero-oligomers prepared by enzymatic synthesis and NaTFSI
Shivam, Kumar, Agrawal, Omnarayan , Mukherjee, Monalisa , Pandey, Mukesh K. , Parmar, Virinder S. , Vittadello, Michele , Pandey, Mukesh K , Kumar, Sumit , Patra, Ranjan

Mayo Clinic

Journal of Materials Chemistry A | September 11, 2025 | Volume: 13 | Issue: 39 | Pages: 33880-33896

10.1039/d4ta09004g Get It

New solvent-free polymer electrolytes are proposed based on a linear perfluorinated copolymer synthesized by enzymatic methods. The system is biphasic and exhibits two distinct conductivity pathways for long-range Na + -cation migration.